Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › orforglipron

orforglipron

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of orforglipron

3 trials tracked of orforglipron: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 78 citations.

3Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 1 2
  1. Phase 3 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone Completed · 78 cited
  2. Phase 1 A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants Completed
  3. Phase 1 A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin
Diabetes & Endocrinology RCT
Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin A New Diabetes Pill Takes On Ozempic's Oral Cousin
A phase 3 RCT of 1698 adults with type 2 diabetes inadequately controlled on metformin found that once-daily oral orforglipron (12 mg or 36 …
A new once-daily diabetes pill called orforglipron lowered blood sugar better than oral semaglutide in a major head-to-head trial, but at th…
Apr 14, 2026
FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities
Diabetes & Endocrinology FDA Approval
FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities The FDA has approved a new daily pill called FOUNDAYO to help adults manage their weight
The FDA has approved FOUNDAYO (orforglipron), an oral GLP-1 receptor agonist, for chronic weight management in adults with obesity or overwe…
FDA approves new daily pill FOUNDAYO for adults to manage weight alongside diet and exercise.
FDA Apr 3, 2026